Lifeward Ltd
Lifeward Ltd provides medical equipment, supplies, and distribution services within the healthcare sector, generating revenue primarily through the sale and distribution of medical products and services.
Business. Lifeward Ltd (LFWD.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, including capital equipment and consumables. Lifeward is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Lifeward Ltd (LFWD.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, including capital equipment and consumables. Lifeward is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Lifeward Ltd's capital structure is characterized by a debt-to-equity ratio of 0.33, indicating a relatively conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 1.31, suggesting it can cover its short-term obligations but with limited buffer. The company's cash and equivalents amount to $2.17 million, while its long-term debt is $2.80 million, resulting in a net cash position that is negative after subtracting total debt.
Profitability metrics for Lifeward Ltd are weak, with a return on equity (ROE) of -2.37 and a return on assets (ROA) of -0.87, both significantly below the industry median for medical equipment and supplies. The company reported a net loss of $19.91 million and an operating loss of $19.67 million, indicating a challenging operating environment. Gross profit of $8.43 million on $22.03 million in revenue suggests a gross margin of 38.3%, which is in line with the industry but insufficient to offset operating costs.
Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the absence of segment-specific revenue breakdowns limits the ability to assess geographic or product diversification. The company operates in a single business sector, which may increase its exposure to sector-specific risks.
The company's growth trajectory is uncertain, with no specific revenue growth or decline figures provided for the current or next fiscal year. The operating cash flow of -$16.83 million and free cash flow of -$19.60 million indicate a cash outflow, which could constrain the company's ability to invest in growth initiatives. The capital expenditure of -$16,000 is minimal, suggesting limited investment in physical assets.
Risk factors for Lifeward Ltd include liquidity constraints and the potential for dilution, although the latter is currently assessed as low. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in maintaining liquidity. The absence of strong buy recommendations from analysts and the presence of only two buy ratings suggest a cautious outlook from the investment community.
Recent events and filings do not provide specific details on material developments for Lifeward Ltd. The company's financial performance and operational results are disclosed in its latest financial statements, but no significant events or earnings call transcripts are highlighted in the available data.
- Lifeward Ltd is operating at a net loss with a negative return on equity and assets, indicating poor profitability.
- The company's liquidity is medium, with a current ratio of 1.31 and a negative net cash position after subtracting total debt.
- Analysts have issued a mean price target of $20.00, but no strong buy recommendations, reflecting a cautious outlook.
- The company's capital expenditures are minimal, and its operating cash flow is negative, suggesting limited investment in growth.
- The absence of segment-specific revenue data limits the ability to assess geographic or product diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -2,58 |
| Revenue | —no estimate | —no estimate | 30,1M USD |
| Operating income | —no estimate | —no estimate | -15,6M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, President & CEO · Option (Right to Buy) → Ordinary Shares, no par value per shareAcquired 172 698 @ $6,53grant · 2026-03-25
- Chief Financial Officer · Option (Right to Buy) → Ordinary Shares, no par value per shareAcquired 39 934 @ $6,53grant · 2026-03-25
- Chief Financial Officer · Option (Right to Buy) → Ordinary Shares, par value NIS 1.75 per shareAcquired 225 000 @ $0,72grant · 2025-08-13
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Lifeward Ltd Market data — financials · 2026-05-28
- Lifeward Ltd Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Chief Medical Officer · Ordinary Shares, no par value per shareOther 15 000 · 2026-05-01
- Director · Ordinary Shares, no par value per shareOther 7 657 · 2026-03-25
- Director · Ordinary Shares, no par value per shareOther 11 485 · 2026-03-25
- Director · Ordinary Shares, no par value per shareOther 11 485 · 2026-03-25
- Director · Ordinary Shares, no par value per shareOther 7 657 · 2026-03-25
- Director · Ordinary Shares, no par value per shareOther 7 657 · 2026-03-25
- VP of Market Access & Strategy · Ordinary Shares, par value NIS 1.75 per shareOther 50 000 · 2025-12-11
- VP of Market Access & Strategy · Ordinary Shares, par value NIS 1.75 per shareSold 1 591 @ $0,64$1K · 2025-09-02
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 24.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -24.9%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -55.4%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -14.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -29.8%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 33.0%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 2.6%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.31xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -67.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.72xDerived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 31.2%Derived (calculated)
- Net margin (FY 2025-12-31): -90.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
- Return on assets (FY 2025-12-31): -87.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 22.5%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -22.0%Derived (calculated)
- Return on equity (FY 2025-12-31): -236.8%Derived (calculated)
- Gross margin (FY 2025-12-31): 38.2%Derived (calculated)
- Pre-tax income (annual): USD -19.97MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -17SEC XBRL filing
- Cost of revenue (annual): USD 13.61MSEC XBRL filing
- Total liabilities (annual): USD 14.49MSEC XBRL filing
- Current assets (annual): USD 15.81MSEC XBRL filing